Violeta Serra

Violeta Serra

UNVERIFIED PROFILE

Are you Violeta Serra?   Register this Author

Register author
Violeta Serra

Violeta Serra

Publications by authors named "Violeta Serra"

Are you Violeta Serra?   Register this Author

60Publications

2301Reads

26Profile Views

Controversies in oncology: are genomic tests quantifying homologous recombination repair deficiency (HRD) useful for treatment decision making?

ESMO Open 2019 9;4(2):e000480. Epub 2019 May 9.

High Risk and Cancer Prevention Group, Vall d'Hebron Institut d'Oncologia, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/esmoopen-2018-000480DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555601PMC
May 2019

Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy.

J Clin Oncol 2018 11 21;36(31):3134-3143. Epub 2018 Sep 21.

Cristina Cruz and Judith Balmaña, Vall d'Hebron Hospital; Cristina Cruz, Alba Llop-Guevara, Joaquín Arribas, Ana Vivancos, Violeta Serra, and Judith Balmaña, Vall d'Hebron Institute of Oncology; José A. Pérez Fidalgo, Ana Lluch, Joaquín Arribas, and Violeta Serra, Centro de Investigación Biomédica en Red; Joaquín Arribas, Institució Catalana de Recerca i Estudis Avançats, Barcelona; José A. Pérez Fidalgo and Ana Lluch, Hospital Clínico de Valencia, Valencia; Cristian Fernández, Carmen Kahatt, Carlos M. Galmarini, Arturo Soto-Matos, Vicente Alfaro, and Aitor Pérez de la Haza, PharmaMar, Madrid; Silvia Antolin, Complejo Universitario Hospitalario La Coruña, La Coruña; Rafael Lopez, Complejo Hospitalario Universitario Santiago de Compostela, Santiago de Compostela, Spain; Judy E. Garber, Dana Farber Cancer Institute; Nadine M. Tung, Beth Israel Deaconess Medical Center; José Baselga and Steven J. Isakoff, Massachusetts General Hospital Cancer Center, Boston, MA; Banu K. Arun, MD Anderson Cancer Center, Houston, TX; Melinda L. Telli, Stanford University School of Medicine, Stanford, CA; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; and Linda Vahdat, Weill Cornell Medicine, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.78.6558DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209089PMC
November 2018

Targeting p38α Increases DNA Damage, Chromosome Instability, and the Anti-tumoral Response to Taxanes in Breast Cancer Cells.

Cancer Cell 2018 06 24;33(6):1094-1110.e8. Epub 2018 May 24.

Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology, Barcelona 08028, Spain; ICREA, Pg. Lluís Companys 23, Barcelona 08010, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2018.04.010DOI Listing
June 2018

Coamplification of protects -amplified breast cancers from targeted therapy.

Proc Natl Acad Sci U S A 2018 03 23;115(11):E2594-E2603. Epub 2018 Feb 23.

Department of Oral and Craniofacial Molecular Biology, Philips Institute for Oral Health Research, VCU School of Dentistry and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1717820115DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5856537PMC
March 2018

Modulation of telomere protection by the PI3K/AKT pathway.

Nat Commun 2017 11 2;8(1):1278. Epub 2017 Nov 2.

Telomeres and Telomerase Group, Molecular Oncology Program, Spanish National Cancer Centre (CNIO), Melchor Fernández Almagro 3, Madrid, E-28029, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41467-017-01329-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668434PMC
November 2017

Sensitizing HR-proficient cancers to PARP inhibitors.

Mol Cell Oncol 2017 3;4(6):e1299272. Epub 2017 Mar 3.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/23723556.2017.1299272DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706951PMC
March 2017

A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds.

Cell 2016 09 15;167(1):260-274.e22. Epub 2016 Sep 15.

Department of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge CB2 0RE, UK; Cambridge Breast Unit, NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre at Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 2QQ, UK. Electronic address:

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5037319PMC
http://dx.doi.org/10.1016/j.cell.2016.08.041DOI Listing
September 2016

Cancer network activity associated with therapeutic response and synergism.

Genome Med 2016 08 24;8(1):88. Epub 2016 Aug 24.

Breast Cancer and Systems Biology Lab, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), Gran via 199, L'Hospitalet del Llobregat, Barcelona, 08908, Catalonia, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13073-016-0340-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995628PMC
August 2016

PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.

Sci Transl Med 2015 Apr;7(283):283ra51

Human Oncology and Pathogenesis Program and Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, New York, NY 10065, USA. Breast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Weill Cornell Medical College, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scitranslmed.aaa4442DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433148PMC
April 2015

Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy.

J Natl Cancer Inst 2014 Nov 24;106(11). Epub 2014 Sep 24.

*Authors contributed equally to this work.Affiliations of authors: Preclinical Research (JLPP, BM, ME, RV, MZF, KP, VS, AP, JA) and Clinical Research Programs (PN, JC, ITR), Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Pathology Department, Vall d'Hebron University Hospital, Barcelona, Spain (VP); Human Oncology and Pathogenesis Program (HOPP) and Memorial Sloan Kettering Cancer Center, New York, NY (MS, JB); Instituto de Biología Molecular y Celular del Cáncer, Campus Miguel de Unamuno, Salamanca, Spain (AP); Lineberger Comprehensive Cancer Center, Chapel Hill, NC (CMP); Department of Biochemistry and Molecular Biology, Universitat Autonoma de Barcelona, Campus de la UAB, Bellaterra, Spain (JA); Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain (JA).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju291DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4271027PMC
November 2014

Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors.

Mol Cancer Ther 2014 May 18;13(5):1021-31. Epub 2014 Apr 18.

Authors' Affiliations: Molecular Therapeutics Research Unit, Medical Oncology Department; and Experimental Therapeutics Group, Vall d'Hebron University Hospital, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-13-0639DOI Listing
May 2014

Evaluation and clinical analyses of downstream targets of the Akt inhibitor GDC-0068.

Clin Cancer Res 2013 Dec 18;19(24):6976-86. Epub 2013 Oct 18.

Authors' Affiliations: Oncology Biomarker Development, Portfolio Management and Operations, Translational Oncology, Biostatistics, and Exploratory Clinical Development, Genentech Inc., DNA Way, South San Francisco, California; Experimental Therapeutics, Molecular Pathology, Breast Cancer and Melanoma, Gastrointestinal and Endocrine Tumors Groups, and Medical Oncology Service, Vall d'Hebron Institute of Oncology, Barcelona; Department of Hematology and Medical Oncology, Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain; and Human Oncology and Pathogenesis Program and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-0978DOI Listing
December 2013

Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel HER2V659E mutation.

Cancer Discov 2013 Nov 15;3(11):1238-44. Epub 2013 Aug 15.

1Vall d'Hebron Institut d'Oncologia; 2Vall d'Hebron Institut de Recerca; 3Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona; 4Instituto Universitario de Oncología, Universidad de Oviedo, Oviedo, Spain; and 5Human Oncology & Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-0132DOI Listing
November 2013

Development of PI3K inhibitors: lessons learned from early clinical trials.

Nat Rev Clin Oncol 2013 Mar 12;10(3):143-53. Epub 2013 Feb 12.

Medical Oncology Department, Vall d'Hebrón University Hospital, Universitat Autònoma de Barcelona, Passeig Vall d'Hebron 119, Edifici Maternoinfantil Planta 14, 08035 Barcelona, Spain.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/nrclinonc.2013.10
Publisher Site
http://dx.doi.org/10.1038/nrclinonc.2013.10DOI Listing
March 2013

Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.

Clin Cancer Res 2012 May 8;18(9):2603-12. Epub 2012 Mar 8.

Department of Experimental Therapeutics Laboratory, Vall d'Hebron Institute of Oncology, Pg Vall d'Hebron, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-11-2750DOI Listing
May 2012

Functional transcriptomics: an experimental basis for understanding the systems biology for cancer cells.

Adv Enzyme Regul 2007 1;47:41-62. Epub 2007 Mar 1.

Laboratory of Molecular Tumor Pathology, Charité-Universitätsmedizin Berlin, Charitéplatz 1, D-10117 Berlin, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.advenzreg.2006.12.001DOI Listing
November 2007

Analysis of gene expression profiles in melanoma cells with acquired resistance against antineoplastic drugs.

Melanoma Res 2006 Apr;16(2):147-55

Institute of Pathology, Charité Campus Mitte, Universitätsmedizin Berlin, Berlin, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.cmr.0000215037.23188.58DOI Listing
April 2006

Telomere shortening in human fibroblasts is not dependent on the size of the telomeric-3'-overhang.

Aging Cell 2004 Jun;3(3):103-9

Henry Wellcome Biogerontology Laboratory, University of Newcastle upon Tyne, Newcastle upon Tyne, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1474-9728.2004.00094.xDOI Listing
June 2004

Extracellular superoxide dismutase is a major antioxidant in human fibroblasts and slows telomere shortening.

J Biol Chem 2003 Feb 9;278(9):6824-30. Epub 2002 Dec 9.

Institute of Pathology and Research Laboratory Cardiology, Charité Hospital, D-10098 Berlin, Germany.

View Article

Download full-text PDF

Source
http://www.jbc.org/lookup/doi/10.1074/jbc.M207939200
Publisher Site
http://dx.doi.org/10.1074/jbc.M207939200DOI Listing
February 2003

Human fibroblasts in vitro senesce with a donor-specific telomere length.

FEBS Lett 2002 Apr;516(1-3):71-4

Institute of Pathology, Charite, Humboldt University Berlin, Berlin, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0014-5793(02)02504-8DOI Listing
April 2002